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1  | WHAT IS THE IMPAC T OF OBESIT Y 
AND METABOLIC SYNDROME ON LIVING 
KIDNE Y DONATION?
Obesity among adults in the United States has grown from 22.9% in 
1988 to 38.8% in 2016, with African American and Hispanic popu‐
lations having disproportionately high rates of obesity (47.9% and 
44.8%, respectively).1 Likewise, morbid obesity has increased from 
8.1% to 17.6% over the same period. These shifts have directly af‐
fected the living kidney donor (LKD) population, with 22.8% of LKDs 
being obese and 2.4% being morbidly obese in 2016 according to 
United Network for Organ Sharing (UNOS) data.2,3 However, these 
figures only tell part of the story, as they only report patients who 
have completed donation and fail to capture the magnitude of poten‐
tial LKDs who have been excluded from donation due to obesity or 
related metabolic syndromes.
Currently there is no universally accepted BMI cutoff among 
US transplant centers for potential LKDs, although most centers 
fall between 30 and 35 kg/m2. Limited data from single‐center 
studies demonstrate that exclusion rates for obesity vary from 
1.8% to 25%.4‐10 Similar rates of exclusion apply to hypertension 
(7.6% to 21%), although exclusion due to diabetes is relatively rare 
(1.2% to 3.5%). Exclusion rates due to obesity‐related comorbid‐
ities may be underestimations, as patients are more likely to be 
excluded for self‐reported obesity during initial phone screening 
than for undiagnosed comorbidities that are discovered during 
transplant donor clinic visit.
For those patients with obesity who move forward with dona‐
tion, single‐center studies report inferior postdonation outcomes 
for both donors and recipients. When compared to normal‐weight 
donors, obese donors are more likely to experience short‐term 
postoperative decline in estimated GFR (eGFR) and have a higher 
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The obesity epidemic has gripped the transplant community. With nearly 40% of 
adults	 in	 the	United	States	being	obese	 (BMI	≥30	kg/m2) and 20% being morbidly 
obese	(BMI	≥35	kg/m2), the implications for both donors and recipients of solid or‐
gans continue to grow.1 Nowhere is this more impactful than the candidacy of living 
kidney donors (LKDs). As increasing numbers of obese adults present for LKD consid‐
eration and evidence of inferior outcomes among obese LKDs grows, transplant sur‐
geons will become progressively challenged by how to manage these patients in the 
clinic. Therefore, we offer this Personal Viewpoint to the transplant surgery commu‐
nity in order to review the current impact of obesity on living kidney donation, high‐
light what weight‐loss interventions have already been attempted, and discuss the 
role that referral for weight‐loss interventions including bariatric surgery might have 
going forward.
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long‐term risk of developing end‐stage renal disease (ESRD) 
(adjusted hazard ratio [aHR] 1.86, 95% confidence interval [CI] 
1.05‐3.30), that is dose‐dependent (7% increase in ESRD risk for 
each unit increase in BMI above 27 kg/m2) 11‐13 (Table 1). They also 
have higher postdonation rates of newly diagnosed diabetes (up 
to 6.3%), cardiovascular disease (up to 8.3%), hypertension (up 
to 69%), abnormal high‐density lipoprotein (up to 44%), microal‐
buminuria (up to 21%), and further weight gain (up to 35%).14‐16 
These rates are exceptional given that patients with elevated 
BMI are often more scrutinized than normal‐weight donors for 
borderline comorbidities. Recipients of kidney from obese LKDs 
also do worse—they experience a higher risk of graft loss (aHR per 
10 kg/m2 increase in BMI 1.12, 95% CI 1.04‐1.21), and recipients 
of kidneys from donors who later develop ESRD have a higher risk 
of mortality.17,18
2  | WHAT INTERVENTIONS HAVE BEEN 
TRIALED FOR POTENTIAL LKDS WITH 
OBESIT Y?
Given that up to one‐fourth of potential LKDs are excluded due to 
obesity and that those who complete donation have alarmingly high 
postdonation risks, interventions to encourage weight loss before 
donation seem obvious. However, published literature on weight‐loss 
interventions for potential LKDs with obesity is sparse, with data on 
bariatric surgery essentially nonexistent. Only one retrospective, ob‐
servational study has reported outcomes from a monitored diet pro‐
gram with lifestyle modifications for potential LKDs.5 In this study, 
Sachdeva et al analyzed 23 morbidly obese patients who were ex‐
cluded from initial living kidney donation due to their weight (BMI 
≥35	kg/m2). These patients received individualized recommenda‐
tions for diet and lifestyle modifications by a transplant nutritionist 
and were followed with monthly phone calls. Even in this group of 
highly motivated patients, only 3 (13%) lost enough weight to attain a 
BMI <35 kg/m2 and then undergo donation. No long‐term outcomes 
were reported and it is uncertain whether these patients regained 
significant weight in the postoperative period.
Only 2 case reports with a total of 3 patients have reported 
outcomes of living kidney donation after predonation bariatric sur‐
gery. First, Branco et al reported a >30% decrease in overall BMI 
and uneventful postoperative courses in 2 patients who underwent 
bariatric surgery in Brazil.19 Second, Koshy et al documented a per‐
centage excess BMI decrease of 54% (BMI 41.5 to 32.6 kg/m2) in 
a patient who underwent laparoscopic gastric banding in Australia. 
Eight months after an uncomplicated donation, the patient's follow‐
up BMI was relatively stable at 33.5 kg/m2. Neither study includes 
long‐term follow‐up outcomes for their patients. Therefore, to un‐
derstand what impact bariatric surgery might have among potential 
LKDs with obesity, its impact on the general population must be 
discussed.
3  | WHAT ARE THE RISKS AND BENEFITS 
OF BARIATRIC SURGERY?
Bariatric surgery is the most successful and longest‐lasting treatment 
for morbid obesity. Current National Institutes of Health (NIH) and 
Centers for Medicare & Medicaid Services (CMS) guidelines for bariat‐
ric	surgery	require	the	patient	to	have	either	(1)	BMI	≥40	kg/m2 or (2) 
BMI 35‐40 kg/m2	with	≥1	obesity‐related	comorbidity	 (eg,	diabetes,	
hypertension, dyslipidemia, heart disease, obstructive sleep apnea, 
and so on), and have been previously unsuccessful with medical treat‐
ment for obesity.20,21 Approximately 216 000 bariatric surgeries were 
performed in the United States in 2016.22 These include the Roux‐en‐Y 
gastric bypass (RYGB), laparoscopic sleeve gastrectomy (LSG), and 
TA B L E  1   Summary table of donor outcomes after obese living kidney donation, recipient outcomes after obese living kidney donation, 
and outcomes after bariatric surgery in the general population
Donor outcomes after obese living 
kidney donation
Recipient outcomes after obese living 
kidney donation Bariatric surgery outcomes in general population
• Higher long‐term risk of developing 
ESRD that is dose‐dependent per 
unit BMI above 27 kg/m2
• Higher post‐donation rates of de 
novo diabetes, hypertension, and 
dyslipidemia 
• More likely to experience 
short‐term postdonation decline in 
eGFR
• More likely to experience further 
weight gain
• Increased risk of graft loss that is 
dose‐dependent (12% increased risk per 
10‐unit increase in donor BMI)
• Increased risk of mortality for recipients 
of kidneys whose living donors subse‐
quently developed ESRD
• One‐year excess BMI decrease of 49%‐72% that is 
sustained at 5‐years





• Long‐term rates of reoperation: 
Hernia (2%‐8%)
GERD (5%‐10%)





ESRD, end‐stage renal disease; eGFR, estimated GFR; GERD, gastroesophageal reflux disease.
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revision surgery (ie, LSG to RYGB). The most common operation today 
is LSG, accounting for 70% of primary bariatric operative procedures 
[Figure 1]. Given the association of RYGB with oxalate nephropathy, 
we maintain that barring contraindication, LSG should be the recom‐
mended procedure for morbidly obese potential LKDs and will focus 
on the risks and benefits of LSG for this section (Table 1).
Four recent clinical trials have shown excellent short‐ and long‐
term outcomes for LSG. First, the Swiss Multicentre Bypass or Sleeve 
Study (SM‐BOSS) enrolled 217 patients from 4 Swiss centers com‐
paring LSG to RYGB.23,24 Of the LSG patients (n = 101), percentage 
excess BMI loss at 1 year = 72.4% and 5 years = 61.1% (Figure 2). At 
5 years, many LSG patients showed complete remission in diabetes 
(n = 16/26, 61.5%), hypertension (n = 40/64, 62.5%), dyslipidemia 
(n = 29/68, 42.6%), and hyperuricemia (n = 15/15, 100%). Second, 
the Sleeve vs Bypass (SLEEVEPASS) randomized clinical equiva‐
lence trial recruited 240 patients from Finish centers comparing LSG 
to RYGB.25,26 Similar to the SM‐BOSS trial, LSG patients (n = 121) 
experienced durable weight loss (% excess BMI loss at 1 year = 
57.8% and 5 years = 48.4%), and complete remissions in diabetes 
(n = 5/41, 12.2%), hypertension (n = 20/68, 29.4%), and dyslipidemia 
(n = 14/30, 46.7%). Third, the Surgical Therapy And Medications 
Potentially Eradicate Diabetes Efficiently (STAMPEDE) randomized 
control trial at the Cleveland Clinic recruited 150 patients with type 
2 diabetes to undergo medical therapy, RYGB, or LSG.27‐29 Of the 
LSG patients (n = 47), percentage excess BMI loss at 1 year = 82.7% 
and 5 years = 60.9%, with complete diabetes remission in 23.4% 
(n = 11/47) of patients. Finally, Reges et al performed a retrospective 
cohort study comparing bariatric surgery with nonsurgical obesity 
management in a large Israeli integrated health care fund covering 
54% of all Israeli citizens with 96.8% follow‐up.30 After a median fol‐
low‐up of 4.5 years, the LSG subgroup (n = 3362) had a median % 
excess BMI decrease of 69.0%, with 70.8% of patients experiencing 
a	≥20%	decrease	in	overall	BMI.
Overall, the risks of major complications after LSG are low. 
The Metabolic and Bariatric Surgery Accreditation and Quality 
Improvement Program (MBSAQIP) captures 30‐day outcomes 
for >98% of bariatric operations performed in the United 
States. According to unpublished 2015‐2016 MBSAQIP data 
(N = 212,543 LSG operations), the 30‐day mortality rate after 
LSG is <0.1% and Clavien‐Dindo III+IV complication rate is 2.1%. 
The published long‐term complications after LSG include hernia 
requiring reoperation (2% to 8%) and the development or worsen‐
ing of gastroesophageal reflux disease (GERD) in up to two‐thirds 
of LSG patients that occasionally requires revision to RYGB (5% 
to 10% of all LSG operations).23,25,29,30 Finally, de novo develop‐
ment of obesity‐related comorbidities after LSG is infrequent: 
diabetes = 0.0% to 0.2%, hypertension = 1% to 5%, and dyslipid‐
emia = 2% to 9%.23,30
4  | WHAT ARE BARRIERS TO BARIATRIC 
SURGERY IN POTENTIAL LKDS WITH 
OBESIT Y?
Given the long‐term benefits and low‐risk profile of bariatric surgery 
in the general population, its application to potential LKDs with mor‐
bid obesity seems self‐evident. However, there are aspects of care 
unique to potential LKDs that make this less straightforward. These 
barriers center on 4 main areas: (1) ethically broaching the topic of 
obesity and weight‐loss clinic referral in the transplant clinic setting; 
(2) payment source for weight‐loss interventions; (3) subsequent 
decision for donor candidacy and timing of donation after bariatric 
surgery; and (4) paucity of outcomes data for donation after bariatric 
surgery.
Ethically broaching the topic of obesity and weight loss clinic re‐
ferral with potential LKDs in the transplant clinic will be a complex 
and nuanced topic. Potential LKDs are the most benevolent patients 
that transplant surgeons encounter—they are willing to donate an 
organ to help another person. However, this makes them a vulner‐
able population, where family pressures and feelings of guilt may 
F I G U R E  1   Metabolic and bariatric 
surgery procedure trend, 2011‐2016.22 
RYGB, Roux‐en‐Y gastric bypass; BPD/DS, 
biliopancreatic diversion with duodenal 
switch [Color figure can be viewed at 
wileyonlinelibrary.com]
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compromise their individual autonomy. Reese et al recently showed 
that feelings of disappointment, distress, and loss of life purpose are 
not uncommon among potential LKDs who are turned down for do‐
nation.31 Unless these factors are acknowledged, inadvertent coer‐
cion is possible.
During the discussion in the transplant clinic, 3 central steps 
must be taken. First, potential LKDs with obesity should be informed 
of the reason(s) that they are denied donation. This disclosure should 
be compassionate yet honest. Second, referral to an independent, 
comprehensive weight‐loss and bariatric surgery clinic should be 
offered. This will be a difficult part of the conversation—certain pa‐
tients will be caught off guard, some might feel resentful, and others 
might even see it as coercive (eg, “transplant surgeons want to put 
me through bariatric surgery just so they can remove my kidney”). 
During the discussion for referral, it must be made clear that the de‐
cision for any weight‐loss intervention is predicated on the potential 
LKD's benefit alone, irrespective of possible future benefit to the 
intended recipient. As such, referral to an independent clinic for an 
unbiased discussion of the risks and benefits of weight‐loss options 
is obligatory. Even if the potential LKD does not meet NIH/CMS 
criteria for bariatric surgery (ie, BMI 30‐35 kg/m2), referral to an 
independent clinic is useful for facilitation of other weight‐loss inter‐
ventions (ie, medications, diet/exercise) and to establish longitudinal 
follow‐up. Finally, it must be made absolutely clear that successful 
weight loss may not result in ultimate donation to the intended re‐
cipient; other living or deceased donors might present before the 
potential LKD is eligible for donation, so ultimate donation cannot 
be promised.
F I G U R E  2   Percentage excess weight 
loss over 5‐year follow‐up for individual 
patients after laparoscopic sleeve 
gastrectomy from the (A) SLEEVEPASS 
and (B) SM‐BOSS randomized clinical 
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Second, payment for weight‐loss clinic referral or bariatric sur‐
gery might become controversial. Normally, all expenses related to 
donation and subsequent care are paid in‐full by the recipient's in‐
surance. However, this arrangement is improper for obesity‐related 
expenses among potential LKDs. Because the decisions for weight‐
loss clinic referral and interventions are based on the potential LKD's 
health alone, payment by the intended recipient's insurance would 
be unethical and potentially coercive. Even so, one caveat exists. As 
described by Issa et al, LKDs who are initially obese but lose sufficient 
weight by diet and exercise in the predonation period to then undergo 
donation are more likely to regain it afterward and consequently have 
increased risk of developing future hypertension (relative risk [RR] 
1.93, 95% CI 1.51‐2.46) and diabetes (RR 4.18, 95% CI 2.05‐8.50).32 
For these patients, we suggest that payment by the recipient's insur‐
ance for weight‐loss clinic referral and/or bariatric surgery is appro‐
priate, as their previous donation puts them at higher risk of adverse 
outcomes from obesity. One critical area of future research related to 
this will be defining BMI cutoffs for bariatric surgery in patients who 
have already undergone donation. We propose that previous dona‐
tion should be akin to an “obesity‐related comorbidity” and allow pre‐
vious	LKDs	to	undergo	bariatric	surgery	at	a	BMI	≥35	kg/m2 cutoff, 
even without other obesity‐related comorbidities such as hyperten‐
sion or diabetes. However, this requires further study.
Third, determination of donor candidacy after bariatric surgery 
and timing of subsequent donation must be established. Given that 
sufficient weight loss is not guaranteed by any intervention and devel‐
opment of de novo obesity‐related comorbidities is rare but possible, 
we discourage donation until potential LKDs meet prespecified trans‐
plant center donation eligibility requirements (ie, BMI <30 kg/m2 with 
nonprohibitive comorbidities) and have been stable with these char‐
acteristics	for	≥3	months.	The	first	requirement	is	essential	because	
potential LKDs should not be allowed to donate if they do not meet 
prespecified standards beforehand. The second requirement of sta‐
ble	eligibility	 for	≥3	months	before	donation	must	be	prospectively	
validated. One additional question for donor candidacy after bariatric 
surgery is whether age should influence this decision. Little is known 
about maintenance of weight loss beyond 5 years following bariatric 
surgery, and it is possible that compared to older patients, younger 
patients have a greater chance of regaining weight and/or comorbid 
conditions over a longer lifetime. Currently, there is insufficient evi‐
dence to recommend an “age minimum” for donation after bariatric 
surgery, but transplant surgeons must keep this possible long‐term 
risk in mind when counseling younger potential LKDs on donation.
Finally, donor and recipient outcomes following donation after 
bariatric surgery are unknown. Existing evidence can be extrapo‐
lated to suggest that donation after bariatric surgery would have 
acceptable donor outcomes, but there have been no studies ex‐
amining this. Furthermore, it is uncertain whether sufficient donor 
weight loss preoperatively will mitigate the known increased risk of 
recipient graft loss from obese donors. We propose that retrospec‐
tive outcomes analyses of LKDs with a remote history of bariatric 
surgery would be the first step to bridge these knowledge gaps.
5  | CONCLUSION
The growing influx of obese LKD candidates will force transplant 
centers to design innovative solutions to optimally manage these 
patients. Donation with obesity portends real risks to living donors, 
and early referral to an independent, comprehensive weight‐loss and 
bariatric surgery clinic may offer a unique and evidence‐supported 
opportunity to improve the health of prospective LKDs with obe‐
sity. Transplant surgeons must become comfortable with facilitating 
these	referrals	for	all	potential	LKDs	with	BMI	≥30	kg/m2. Ultimate 
weight‐loss management decisions should be consistent with exist‐
ing NIH/CMS guidelines and made between the patient and an in‐
dependent physician. Future research is needed to determine the 
appropriate donor candidacy after weight‐loss interventions, opti‐
mal timing of donation following bariatric surgery, and suitable BMI 
cutoff for bariatric surgery among previous LKDs who go on to de‐
velop obesity.
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